Par4 inhibitor therapy for patients with par4 polymorphism
AssigneeThomas Jefferson University
InventorsPaul Bray, Michael Holinstat, Leonard Edelstein
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for determining whether a PAR4 inhibitor should be administered to a human subject, the methods comprising administering a PAR4 inhibitor to a subject determined to have a “G” allele for a single-nucleotide polymorphism (SNP) at rs773902, and not administering a PAR4 inhibitor to a subject determined to have an “A” allele for the SNP at rs773902. A genotyping assay can be used to determine the SNP.
Claims20
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of preventing or treating thrombosis in a human subject who is (a) being administered a P2Y12 inhibitor and (b) has a “G” allele for a single-nucleotide polymorphism (SNP) at rs773902;
- the method comprising (a) stopping administration of the P2Y12 inhibitor and (b) administering a therapeutically effective amount of a PAR4 inhibitor.
A method of preventing or treating thrombosis in a human subject comprising:
- (a) subjecting a test sample obtained from the human subject to a genotyping assay adapted to determine the genotype of the SNP at rs773902;
- (b) determining whether the polymorphism at rs773902 has a “G” allele or an “A” allele, and (c) administering to a patient having a “G allele a PAR4 inhibitor and administering to said patient with the “A” allele a therapeutic that is not a PAR4 inhibitor.
Dependencies are inferred from the claim text.